Compare

Jazz Pharmaceuticals/$JAZZ

1D1W1M3M6MYTD1Y5YMAX

About Jazz Pharmaceuticals

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Ticker
$JAZZ
Sector
Health
Primary listing
NASDAQ
Employees
2,890
Headquarters
Dublin, Ireland

JAZZ Metrics

BasicAdvanced
$15B
77.69
$3.10
0.37
-

What the Analysts think about JAZZ

Analyst ratings (Buy, Hold, Sell) for Jazz Pharmaceuticals stock.
Analyst projections of the future price of Jazz Pharmaceuticals stock.

Bulls say / Bears say

Third-quarter revenue reached a record $1.24bn, up 10% year on year, and Jazz raised its 2026 revenue guidance to $4.775bn–$4.85bn. Growth across Xywav and oncology, plus Modeyso sales, supports the case that momentum is broadening. (Jazz Pharmaceuticals)
The FDA approved Ziihera combinations for first-line HER2-positive gastroesophageal cancer, extending the drug into a larger treatment setting. In the pivotal trial, the combination with chemotherapy and tislelizumab improved median overall survival to 26.4 months from 19.2 months with the comparator. (Jazz Pharmaceuticals)
Xywav sales grew 12% to $483m in the third quarter, with 425 net patient additions. Continued uptake suggests its low-sodium formulation is helping it hold demand despite competition in the sleep-treatment market. (Jazz Pharmaceuticals)
Zepzelca failed to improve overall survival in its confirmatory second-line lung-cancer trial, and Jazz later removed that indication from the label. This cuts off a treatment setting and leaves the growth story more reliant on first-line maintenance use. (Reuters, Jazz Pharmaceuticals)
Generic entry remains a risk to the sleep franchise: Jazz disclosed that a settlement with Granules could allow an early Xywav generic launch in some circumstances, while litigation with Lupin and Teva continues. Earlier-than-expected competition could erode a major revenue stream. (U.S. Securities and Exchange Commission)
At September 30, Jazz had $5.6bn of debt against $2.9bn of cash and investments, leaving about $2.7bn of net debt. That leverage makes the company more exposed if new launches or existing product growth fall short. (Jazz Pharmaceuticals)
Data summarised monthly by Lightyear AI. Last updated on 3 Nov 2026.

JAZZ Financial Performance

Revenues and expenses
Income statement
AnnuallyQuarterly
2023
YoY growth
Revenue
Net income
Profit margin

JAZZ Earnings Performance

Company profitability
Earnings per share
AnnuallyQuarterly
2020
2021
2022
2023
2024
Actual
Expected
Surprise
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.